Tags

Type your tag names separated by a space and hit enter

Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain.
Expert Rev Neurother. 2006 Oct; 6(10):1423-8.ER

Abstract

Ziconotide is a new nonopioid intrathecal agent recently approved for the treatment of chronic pain. Ziconotide is indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine. Ziconotide blocks the N-type calcium channels located in the superficial dorsal horn of the spinal cord, resulting in potent analgesia. The efficacy of ziconotide has been demonstrated in three randomized, placebo-controlled trials in over 500 patients. In addition, its safety has been demonstrated in over 1200 subjects. Ziconotide is a potent analgesic with a narrow therapeutic window. The drug requires a slow titration in order to achieve analgesia while avoiding dose-limiting side effects. This review examines the currently available information on this new analgesic.

Authors+Show Affiliations

Center for Pain Medicine, University of California, San Diego, 9500 Gilman Drive, 0924, San Diego, CA 92093, USA. mswallace@ucsd.edu

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17078783

Citation

Wallace, Mark S.. "Ziconotide: a New Nonopioid Intrathecal Analgesic for the Treatment of Chronic Pain." Expert Review of Neurotherapeutics, vol. 6, no. 10, 2006, pp. 1423-8.
Wallace MS. Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother. 2006;6(10):1423-8.
Wallace, M. S. (2006). Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Review of Neurotherapeutics, 6(10), 1423-8.
Wallace MS. Ziconotide: a New Nonopioid Intrathecal Analgesic for the Treatment of Chronic Pain. Expert Rev Neurother. 2006;6(10):1423-8. PubMed PMID: 17078783.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. A1 - Wallace,Mark S, PY - 2006/11/3/pubmed PY - 2007/1/5/medline PY - 2006/11/3/entrez SP - 1423 EP - 8 JF - Expert review of neurotherapeutics JO - Expert Rev Neurother VL - 6 IS - 10 N2 - Ziconotide is a new nonopioid intrathecal agent recently approved for the treatment of chronic pain. Ziconotide is indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine. Ziconotide blocks the N-type calcium channels located in the superficial dorsal horn of the spinal cord, resulting in potent analgesia. The efficacy of ziconotide has been demonstrated in three randomized, placebo-controlled trials in over 500 patients. In addition, its safety has been demonstrated in over 1200 subjects. Ziconotide is a potent analgesic with a narrow therapeutic window. The drug requires a slow titration in order to achieve analgesia while avoiding dose-limiting side effects. This review examines the currently available information on this new analgesic. SN - 1744-8360 UR - https://www.unboundmedicine.com/medline/citation/17078783/Ziconotide:_a_new_nonopioid_intrathecal_analgesic_for_the_treatment_of_chronic_pain_ L2 - https://www.tandfonline.com/doi/full/10.1586/14737175.6.10.1423 DB - PRIME DP - Unbound Medicine ER -